Bioregenx reported revenue of $0.43M and net income of -$0.13M for the quarter ended Mar 2026, down 17.3% year over year. This income statement covers 18 quarters of results from Dec 2021 through Mar 2026, standardized by Business Quant from the company’s SEC filings.
| Income StatementIncome Statement | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | ||||||||||||||||||
| Revenue | 0.01M | 0.01M | 0.01M | 0.01M | 1.08M | 0.86M | 0.79M | 0.68M | 0.55M | 0.73M | 0.60M | 0.46M | 0.52M | 0.45M | 0.51M | 0.39M | 0.43M | |
| Cost of RevenueCost of Rev | 0.31M | 0.26M | 0.22M | 0.30M | 0.17M | 0.26M | 0.11M | 0.14M | 0.11M | 0.09M | 0.08M | 0.07M | 0.08M | |||||
| Gross Profit | 0.76M | 0.60M | 0.57M | 0.38M | 0.38M | 0.47M | 0.48M | 0.32M | 0.41M | 0.35M | 0.43M | 0.32M | 0.35M | |||||
| Operating items | ||||||||||||||||||
| Amortization - Intangibles | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M | 0.50M | 0.56M | 0.56M | 0.56M | -0.03M | ||||||||
| Operating Interest ExpensesOp. Interest Exp. | 0.05M | 0.05M | 0.05M | 0.05M | 0.07M | 0.07M | 0.07M | 0.08M | 0.07M | |||||||||
| Selling, General & AdministrativeSG&A | 0.77M | 1.00M | 2.96M | 0.49M | 3.41M | 1.40M | 0.24M | 1.87M | 0.59M | 0.46M | 0.43M | 0.55M | 0.40M | |||||
| Other Operating ExpensesOther Opex | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.00M | 0.00M | 0.01M | 0.05M | 0.11M | 0.57M | 16.77M | 0.01M | 0.00M | 0.00M | 0.70M | 0.00M | |
| Operating ExpensesOpex | 0.05M | 0.05M | 0.01M | 0.01M | 0.95M | 1.14M | 3.04M | 0.59M | 3.46M | 1.51M | 0.81M | 18.64M | 0.60M | 0.46M | 0.43M | 1.25M | 0.40M | |
| Operating IncomeOp. Inc | -0.04M | -0.03M | 0.00M | -0.01M | -0.18M | -0.54M | -2.47M | -0.21M | -3.08M | -1.04M | -0.33M | -18.32M | -0.19M | -0.11M | -0.01M | -0.94M | -0.05M | |
| EBIT | -0.04M | -0.03M | 0.00M | -0.01M | -0.18M | -0.54M | -2.47M | -0.21M | -3.08M | -1.04M | -0.33M | -18.32M | -0.19M | -0.11M | -0.01M | -0.94M | -0.05M | |
| Non-operating items | ||||||||||||||||||
| Non Operating Interest Expenses | 0.00M | 0.00M | 0.00M | 0.29M | 0.07M | 0.07M | 0.08M | 0.07M | 0.07M | 0.07M | 0.08M | 0.08M | ||||||
| Other Non Operating IncomeOther Non Op Inc. | 0.45M | 0.10M | ||||||||||||||||
| Non Operating IncomeNon Op. Inc. | -0.05M | -0.05M | -0.05M | -0.32M | -0.07M | -0.07M | -0.07M | -0.07M | 0.02M | |||||||||
| Net income details | ||||||||||||||||||
| EBT | -0.04M | -0.03M | 0.00M | -0.01M | -0.23M | 0.00M | 0.00M | -0.72M | -0.70M | -1.17M | -0.46M | -18.48M | -0.34M | -0.18M | -0.08M | -1.02M | -0.13M | |
| Profit After TaxPAT | -0.04M | -0.03M | 0.00M | -0.01M | -0.23M | 0.00M | 0.00M | -0.72M | -0.70M | -1.17M | -0.46M | -18.48M | -0.34M | -0.18M | -0.08M | -1.02M | -0.13M | |
| Income from Continuing OperationsIncome (Continuing) | -0.04M | -0.03M | 0.00M | -0.01M | -0.23M | 0.00M | 0.00M | -0.72M | -0.70M | -1.17M | -0.46M | -18.48M | -0.34M | -0.18M | -0.08M | -1.02M | -0.13M | |
| Consolidated Net IncomeConsol Net Inc. | -0.04M | -0.03M | 0.00M | -0.01M | -0.23M | 0.00M | 0.00M | -0.72M | -0.70M | -1.17M | -0.46M | -18.48M | -0.34M | -0.18M | -0.08M | -1.02M | -0.13M | |
| Income towards Parent CompanyParent Net Inc | -0.04M | -0.03M | 0.00M | -0.01M | -0.23M | -0.59M | -2.52M | -0.26M | -3.15M | -1.11M | -0.39M | -18.40M | -0.27M | -0.18M | -0.08M | -1.02M | -0.03M | |
| Net Income towards Common StockholdersNet Income | -0.04M | -0.03M | 0.00M | -0.01M | -0.23M | -0.59M | -2.52M | -0.26M | -3.15M | -1.11M | -0.39M | -18.40M | -0.27M | -0.18M | -0.08M | -1.02M | -0.03M | |
| Additional items | ||||||||||||||||||
| EPS (Basic) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EPS (Diluted) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Shares Outstanding | 269.75M | 269.75M | 269.75M | 269.75M | 269.75M | 275.27M | 269.75M | 269.75M | 276.37M | 767.60M | 956.53M | 956.53M | 939.51M | 956.99M | 959.21M | 960.87M | 959.71M | 969.17M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 269.75M | 269.75M | 269.75M | 269.75M | 269.75M | 275.27M | 269.75M | 269.75M | 276.37M | 818.79M | 956.53M | 956.53M | 939.51M | 956.99M | 959.21M | 960.87M | 959.71M | 969.17M |
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 269.75M | 269.75M | 269.75M | 269.75M | 269.75M | 276.75M | 276.75M | 276.75M | 276.37M | 767.60M | 956.53M | 956.53M | 956.99M | 960.29M | 961.16M | 961.99M | 969.02M | 971.58M |
| EBITDA | -0.18M | -0.54M | -2.47M | -0.21M | -2.57M | -0.46M | 0.26M | -17.73M | -0.18M | -0.07M | 0.01M | -0.92M | -0.04M | |||||
| Interest ExpensesInt Expense | 0.05M | 0.05M | 0.05M | 0.33M | 0.07M | 0.13M | 0.14M | 0.17M | 0.15M | 0.07M | 0.07M | 0.08M | 0.08M |
Pull Bioregenx's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=BRGX&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "BRGX", "statement": "IS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=BRGX&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();